Heine O
Zentrum der Frauenheilkunde und Geburtshilfe am Klinikum, Justus-Liebig-Universität Giessen.
Geburtshilfe Frauenheilkd. 1988 Feb;48(2):102-5. doi: 10.1055/s-2008-1035703.
A new gel with sulprostone was applied in a prospective randomized study in 70 patients who were scheduled for termination of 1st trimester pregnancy. Priming was carried out in two equal groups of 25 patients with 50 micrograms or 100 micrograms sulprostone gel respectively; in a control group of 20 patients the gelatinizing agent (Pluronic F 127) was used without sulprostone. The gel, which was produced immediately before the application, was applied intracervically with a semiflexible polyethylene catheter with a constant injection volume in a three-hour interval before the operation. A dilatation response--documented by the free patency of Hegar's dilatator which effortlessly passes the outer and inner uterine cervix--was seen in the therapy group; among these patients an average dilatation of the cervical canal of 8.2 mm (SD +/- 2.25) was achieved. This therapeutic effect was better in primiparae and multiparae compared with nulliparae (p less than 0.05). No statistically significant dose-effect correlation was found between the patients who had been treated with 50 micrograms sulprostone and those who had been treated with the 100 micrograms dosage. Among the side effects a dose-independent spastic lower abdominal pain was seen most frequently; it was noticed in 10 patients. Based on the results of this study it is concluded that cervical priming with sulprostone-pluronic gel can be regarded as a practicable method with a low rate of side effects for preoperative cervical priming in patients scheduled for termination of first trimester pregnancy.
一种含舒前列素的新型凝胶在一项前瞻性随机研究中应用于70例计划终止早孕的患者。将70例患者分为两组,每组25例,分别使用50微克或100微克舒前列素凝胶进行预处理;20例患者作为对照组,使用不含舒前列素的凝胶剂(普朗尼克F127)。应用前即刻制备的凝胶,通过半柔性聚乙烯导管宫颈内给药,在手术前每隔3小时以恒定注射量给药。治疗组出现了扩张反应,通过海格扩张器能轻松通过子宫颈内外口来证明;这些患者宫颈管平均扩张8.2毫米(标准差±2.25)。与未产妇相比,初产妇和经产妇的这种治疗效果更好(p<0.05)。接受50微克舒前列素治疗的患者与接受100微克剂量治疗的患者之间未发现统计学上显著的剂量效应相关性。副作用中最常见的是剂量无关的下腹部痉挛性疼痛;10例患者出现该症状。基于本研究结果得出结论,舒前列素-普朗尼克凝胶宫颈预处理可被视为一种可行的方法,对于计划终止早孕的患者术前宫颈预处理副作用发生率较低。